Zevra Therapeutics (ZVRA) Receivables - Net (2018 - 2025)
Zevra Therapeutics (ZVRA) has disclosed Receivables - Net for 8 consecutive years, with $23.3 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 121.32% year-over-year to $23.3 million, compared with a TTM value of $23.3 million through Dec 2025, up 121.32%, and an annual FY2025 reading of $23.3 million, up 121.32% over the prior year.
- Receivables - Net was $23.3 million for Q4 2025 at Zevra Therapeutics, up from $16.8 million in the prior quarter.
- Across five years, Receivables - Net topped out at $23.3 million in Q4 2025 and bottomed at $1.5 million in Q4 2021.
- Average Receivables - Net over 5 years is $9.7 million, with a median of $8.6 million recorded in 2024.
- Peak annual rise in Receivables - Net hit 443.13% in 2022, while the deepest fall reached 70.64% in 2022.
- Year by year, Receivables - Net stood at $1.5 million in 2021, then soared by 443.13% to $8.3 million in 2022, then skyrocketed by 109.39% to $17.4 million in 2023, then plummeted by 39.52% to $10.5 million in 2024, then surged by 121.32% to $23.3 million in 2025.
- Business Quant data shows Receivables - Net for ZVRA at $23.3 million in Q4 2025, $16.8 million in Q3 2025, and $18.3 million in Q2 2025.